AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Comet Resources Ltd

0.200

0.000

Volume:- -

Turnover:- -

Market Cap:13.83M

PE:-6.78

High:0.200

Open:0.200

Low:0.200

Close:0.200

52wk High:0.200

52wk Low:0.200

Shares:69.16M

Float Shares:26.19M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.030

EPS(LYR):-0.030

ROE:-53.62%

ROA:-16.18%

PB:4.73

PE(LYR):-6.78

Loading ...

Overview Company News Filings

Is Charles River (CRL) Quietly Redefining Its Edge Through Complex Biologics and Vaccine Testing?

Simply Wall St.

Charles River Laboratories International (CRL) Cut 2026 Guidance, Is The Stock Still 11% Undervalued?

Simply Wall St.

Sector Update: Healthcare

MT Newswires Live

GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $11.15 - $11.45, vs. FactSet Est of $11.11

MT Newswires Live

Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Revenue $1.00B, vs. FactSet Est of $977.2M

MT Newswires Live

Tanvex's US Unit Receives FDA Nod for TX05 Cancer Drug Biosimilar; Shares Drop 10%

MT Newswires Live

A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness

Simply Wall St.

Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing

MT Newswires Live

GUIDANCE: (CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08

MT Newswires Live

Is Cheaper Energy and Shipping Altering The Investment Case For Charles River Laboratories (CRL)?

Simply Wall St.

Charles River Laboratories Positioned as 'Leading' CRO as Preclinical R&D Inflection Nears, RBC Says

MT Newswires Live

Does Charles River’s NSG BioLabs Tie-Up Reshape the Bull Case For Charles River Laboratories (CRL)?

Simply Wall St.

Could Charles River (CRL) Using Locus Cell Tie-Up to Reframe Its Asia-Pacific Growth Strategy?

Simply Wall St.

Seikagaku Resubmits U.S. Application for Disc Herniation Drug After Addressing FDA Concerns

MT Newswires Live

Charles River (CRL) Trims 2026 Outlook After Divestitures and Leadership Changes Is The Strategy Working?

Simply Wall St.

GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80 - $11.30

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/CRL.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CRL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CRL.AU\",,,,,undefined,":{"symbol":"CRL.AU","market":"AU","secType":"STK","nameCN":"Comet Resources Ltd","latestPrice":0.2,"timestamp":1787292000000,"preClose":0.2,"halted":9,"volume":0,"delay":0,"changeRate":0,"nameEN":"Comet Resources Ltd","floatShares":26192756,"shares":69159244,"eps":-0.029502,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-21 16:00:00 AEST","open":0.2,"high":0.2,"low":0.2,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.029502,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.2,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CRL.AU\",,,,,undefined,":{"symbol":"CRL.AU","floatShares":26192756,"roa":"-16.18%","roe":"-53.62%","lyrEps":-0.029502,"shares":69159244,"dividePrice":0,"high":0.2,"amplitude":0,"preClose":0.2,"low":0.2,"week52Low":0.2,"pbRate":"4.73","week52High":0.2,"institutionHeld":0,"latestPrice":0.2,"eps":-0.029502,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.029502,"open":0.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRL.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-01-31","symbol":"CRL.AU","reason":null,"defaultRemindTime":1706655600000,"announcedDate":"2024-01-30","type":"delisting","dateTimestamp":1706619600000},{"market":"AU","date":"2022-11-14","symbol":"CRL.AU","defaultRemindTime":1668380400000,"type":"split","dateTimestamp":1668344400000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"AU","date":"2022-07-20","symbol":"CRL.AU","defaultRemindTime":1658275200000,"type":"split","dateTimestamp":1658239200000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRL.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRL.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661521068","title":"Is Charles River (CRL) Quietly Redefining Its Edge Through Complex Biologics and Vaccine Testing?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661521068","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661521068?lang=en_us&edition=fundamental","pubTime":"2026-08-23 13:22","pubTimestamp":1787462562,"startTime":"0","endTime":"0","summary":"Earlier this week, Medigen Vaccine Biologics announced it is partnering with Charles River Laboratories International to characterize and validate the virus seed bank and support Chemistry, Manufacturing, and Controls activities for Medigen’s next-generation multivalent enterovirus vaccine using advanced tools such as Next-Generation Sequencing.\nThe collaboration highlights Charles River’s role as a specialist in complex biologics testing and regulatory readiness, potentially strengthening...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/is-charles-river-crl-quietly-redefining-its-edge-through-com","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/is-charles-river-crl-quietly-redefining-its-edge-through-com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRL","BK4588","BK4530","IE00BFMHRM44.USD","CRL.AU","BK4585","LU0029874061.USD","LU1815336091.USD","BK4121","LU0390134368.USD","LU0757428866.USD","AIPO","LU0128526141.USD","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660641757","title":"Charles River Laboratories International (CRL) Cut 2026 Guidance, Is The Stock Still 11% Undervalued?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660641757","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660641757?lang=en_us&edition=fundamental","pubTime":"2026-08-19 13:12","pubTimestamp":1787116362,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International (CRL) cut its 2026 earnings guidance after reporting a second quarter net loss and slightly lower revenue. The company also continued its share repurchase program during the same period.\nSee our latest analysis for Charles River Laboratories International.\nDespite the cut to 2026 earnings guidance and the recent quarterly net loss, Charles River Laboratories International’s share price has risen strongly over recent months, with a 30-day share price...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-international-crl-cut-2026-guidan","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-international-crl-cut-2026-guidan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK7095","CRO.AU","CRL","NHP","IE00BFMHRM44.USD","LU0128526141.USD","LU1815336091.USD","BK7500","LU0029874061.USD","BK4225","BK4121","BK4585","BK4530","LU0390134368.USD","LU0757428866.USD","CRL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657552216","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2657552216","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657552216?lang=en_us&edition=fundamental","pubTime":"2026-08-06 03:21","pubTimestamp":1785957694,"startTime":"0","endTime":"0","summary":"Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index rising 1.2% and the State Street Health Care Select Sector SPDR ETF  adding 0.9%.The iShares Biotechnology ETF  increased 0.5%.In corporate news, Charles River Laboratories  on Wednesday reported fiscal Q2 non-GAAP earnings and sales above market expectations and raised its 2026 non-GAAP EPS guidance. Its shares jumped nearly 11%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","LU0128526141.USD","BK4585","HCSG","BK7095","LU0029874061.USD","LU1815336091.USD","BK4121","LABU","CRL.AU","BK4581","CRL","XBI","BK4137","LU0390134368.USD","BK4530","IE00BFMHRM44.USD","BK4588","LU0757428866.USD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657546255","title":"GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $11.15 - $11.45, vs. FactSet Est of $11.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2657546255","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657546255?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:13","pubTimestamp":1785928411,"startTime":"0","endTime":"0","summary":"GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $11.15 - $11.45, vs. FactSet Est of $11.11","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRL","CRL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657546972","title":"Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Revenue $1.00B, vs. FactSet Est of $977.2M","url":"https://stock-news.laohu8.com/highlight/detail?id=2657546972","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657546972?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:12","pubTimestamp":1785928327,"startTime":"0","endTime":"0","summary":"Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Revenue $1.00B, vs. FactSet Est of $977.2M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRL","CRL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646875850","title":"Tanvex's US Unit Receives FDA Nod for TX05 Cancer Drug Biosimilar; Shares Drop 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646875850","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646875850?lang=en_us&edition=fundamental","pubTime":"2026-06-25 16:57","pubTimestamp":1782377878,"startTime":"0","endTime":"0","summary":"Tanvex Biopharma's  US unit received a Complete Response Letter  from the US Food and Drug Administration for the biologics license application of TX05, a biosimilar to Herceptin used to treat breast and gastric cancers.Shares slumped about 10% in Thursday's late afternoon trade.The FDA's comments relate to issues at a third-party downstream manufacturing facility, while no concerns were raised regarding the drug substance produced by Tanvex, the pharmaceutical company said.Tanvex is working with the contract manufacturer to address the issues and expects to resubmit the application by the end of July, it said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU0757428866.USD","BK7095","LU0128526141.USD","IE00BFMHRM44.USD","BK4121","CRL","LU1815336091.USD","CRL.AU","LABU","BK4588","LU0390134368.USD","BK4530","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636868724","title":"A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2636868724","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636868724?lang=en_us&edition=fundamental","pubTime":"2026-05-19 23:24","pubTimestamp":1779204295,"startTime":"0","endTime":"0","summary":"Recent share performance and company snapshot\nCharles River Laboratories International (CRL) has been under pressure recently, with the stock down 18% over the past month and 5% over the past 3 months, prompting closer attention from investors.\nThe US based contract research company, which supports drug discovery and safety testing across pharmaceuticals and biotech, currently has a market value of about US$7.3b and last closed at US$149.93 per share.\nSee our latest analysis for Charles River...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4530","LU0757428866.USD","LU1815336091.USD","LU0128526141.USD","IE00BFMHRM44.USD","BK4585","LU0029874061.USD","BK4121","CRL","CRL.AU","LU0390134368.USD","DCF","BK7095","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780320","title":"Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780320","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635780320?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:15","pubTimestamp":1778678103,"startTime":"0","endTime":"0","summary":"Charles River Laboratories  said Wednesday it and Medipost have signed a memorandum of understanding to collaborate on GMP-compliant testing.Financial terms weren't disclosed.Under the MoU, Charles River will offer its services related to biologics quality control, viral testing, release testing, and other GMP-compliant services for the support of Medipost's cell therapy pipeline, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","BK4530","CRL","BK4121","LU0757428866.USD","BK7095","IE00BFMHRM44.USD","LU0390134368.USD","LU0029874061.USD","CRL.AU","LU0128526141.USD","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149812","title":"GUIDANCE: (CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149812","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149812?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:29","pubTimestamp":1778153397,"startTime":"0","endTime":"0","summary":"GUIDANCE: (CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRL.AU","CRL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628793618","title":"Is Cheaper Energy and Shipping Altering The Investment Case For Charles River Laboratories (CRL)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2628793618","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628793618?lang=en_us&edition=fundamental","pubTime":"2026-04-20 00:07","pubTimestamp":1776614862,"startTime":"0","endTime":"0","summary":"Recently, the reopening of the Strait of Hormuz eased global logistics and energy costs, improving operating conditions for healthcare and life sciences companies such as Charles River Laboratories International.\nThis shift in energy and shipping expenses could offer cost relief for Charles River’s research and lab services, potentially supporting margins amid ongoing sector pressures.\nWe’ll now examine how lower energy and logistics costs might influence Charles River Laboratories’ existing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/is-cheaper-energy-and-shipping-altering-the-investment-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/is-cheaper-energy-and-shipping-altering-the-investment-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4530","LU1815336091.USD","BDRY","BK7095","BK4588","LU0390134368.USD","LU0029874061.USD","BK4121","BK4585","IE00BFMHRM44.USD","LU0128526141.USD","CRL.AU","CRL","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627440868","title":"Charles River Laboratories Positioned as 'Leading' CRO as Preclinical R&D Inflection Nears, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2627440868","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627440868?lang=en_us&edition=fundamental","pubTime":"2026-04-14 23:11","pubTimestamp":1776179480,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International's  is positioned as the \"leading\" contract research organization, or CRO, for the acceleration of preclinical research and development into 2027, RBC Capital Markets said in a Monday note.RBC said improving macro conditions appear to be setting up an inflection in research and development spending, potentially starting in H2 and then accelerating through 2027. This expected increase in spending should benefit drive outsourcing to CROs and benefit Charles River Laboratories, the brokerage noted.Charles River Laboratories could also see an opportunity in the ongoing evolution of new alternative methods or NAMs, depending on the company's adoption of NAMS, RBC said.RBC initiated coverage on Charles River Laboratories International with an outperform rating and $215 price target.Price: 181.87, Change: +3.53, Percent Change: +1.98","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK7095","BK4121","CRL","IE00BFMHRM44.USD","LU0128526141.USD","LU0757428866.USD","LU1815336091.USD","LU0390134368.USD","CRL.AU","BK4530","BK4585","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626358114","title":"Does Charles River’s NSG BioLabs Tie-Up Reshape the Bull Case For Charles River Laboratories (CRL)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626358114","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626358114?lang=en_us&edition=fundamental","pubTime":"2026-04-11 00:21","pubTimestamp":1775838092,"startTime":"0","endTime":"0","summary":"Charles River Laboratories and Singapore-based NSG BioLabs recently signed a Memorandum of Understanding to combine NSG Bio’s infrastructure and community platform with Charles River’s global life sciences expertise, aiming to help biotech companies move more efficiently from early research to key development milestones.\nThis collaboration not only expands Charles River’s presence in the Asia-Pacific region but also deepens its role as an end-to-end partner for emerging biotech...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/does-charles-rivers-nsg-biolabs-tie-up-reshape-the-bull-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/does-charles-rivers-nsg-biolabs-tie-up-reshape-the-bull-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0390134368.USD","LU1815336091.USD","LU0029874061.USD","LU0128526141.USD","BK4121","BK4530","BK7095","CRL.AU","BK4585","IE00BFMHRM44.USD","CRL","BK4588","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621086715","title":"Could Charles River (CRL) Using Locus Cell Tie-Up to Reframe Its Asia-Pacific Growth Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621086715","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621086715?lang=en_us&edition=fundamental","pubTime":"2026-03-24 01:10","pubTimestamp":1774285851,"startTime":"0","endTime":"0","summary":"In March 2026, Locus Cell Co., Ltd. announced it had signed a Memorandum of Understanding with Charles River Laboratories to explore collaboration on CMC support, analytical testing, technical development, and related services for advanced therapy developers across Taiwan and the wider Asia-Pacific region.\nThis agreement links Charles River’s global biologics testing expertise with Locus Cell’s cell and gene therapy manufacturing platforms, highlighting a potential build-out of integrated...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/could-charles-river-crl-using-locus-cell-tie-up-to-reframe-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/could-charles-river-crl-using-locus-cell-tie-up-to-reframe-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0029874061.USD","BK4528","CRL.AU","BK4588","LU0128526141.USD","LU0390134368.USD","CRL","BK4551","BK4543","IE00BFMHRM44.USD","LU1815336091.USD","AIYY","BK4023","BK4530","BK7095","BK4585","BK4121","LU0757428866.USD","AI","BK4587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618939123","title":"Seikagaku Resubmits U.S. Application for Disc Herniation Drug After Addressing FDA Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939123","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618939123?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:23","pubTimestamp":1773138223,"startTime":"0","endTime":"0","summary":"Seikagaku  resubmitted its biologics license application to the U.S. FDA for SI-6603 , a potential treatment for lumbar disc herniation, according to its Tokyo bourse filing on Tuesday.The resubmission follows a complete response letter  received in March 2025, which raised no concerns about the drug's clinical efficacy or safety but cited issues related to the manufacturing facility and quality control.The CRL is an FDA notification that an application will not be approved in its current state after review.Seikagaku has since addressed these observations and is working with licensing partner Ferring Pharmaceuticals to pursue approval and offer a new non-surgical option for reducing leg pain associated with the condition.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0029874061.USD","BK4588","BK4530","CRL.AU","CRL","BK4121","BK7095","IE00BFMHRM44.USD","LABU","LU1815336091.USD","LU0757428866.USD","LU0128526141.USD","LU0390134368.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616559908","title":"Charles River (CRL) Trims 2026 Outlook After Divestitures and Leadership Changes Is The Strategy Working?","url":"https://stock-news.laohu8.com/highlight/detail?id=2616559908","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616559908?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:26","pubTimestamp":1772634406,"startTime":"0","endTime":"0","summary":"In February 2026, Charles River Laboratories International reported fourth-quarter and full-year 2025 results showing slightly lower revenue of US$994.23 million for the quarter and US$4.02 billion for the year, a net loss driven in part by US$210.97 million of intangible asset impairments and US$165 million of goodwill impairments, and issued 2026 guidance calling for at least flat to 1.5% reported revenue growth and GAAP EPS of US$6.30 to US$6.80. \nSoon after, the company adjusted its 2026...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-crl-trims-2026-outlook-after-divestitures-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-crl-trims-2026-outlook-after-divestitures-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0390134368.USD","LU1815336091.USD","LU0029874061.USD","LU0128526141.USD","BK4121","BK4530","BK7095","CRL.AU","BK4585","IE00BFMHRM44.USD","CRL","BK4588","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614990081","title":"GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80 - $11.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2614990081","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614990081?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:13","pubTimestamp":1772021623,"startTime":"0","endTime":"0","summary":"GUIDANCE: (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80 - $11.30","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRL","CRL.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}